Filed by Soaring Eagle Acquisition Corp. pursuant to
Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Ginkgo Bioworks, Inc.
Commission File No.: 333-256121
Morgan Stanley Healthcare Conference 2021
Ginkgo
Bioworks Fireside Chat
September 9, 2021
Tejas Savant (00:00):
Hey everyone. Good morning. Thanks
for joining us today on day one of our healthcare conference. Im Tejas Savant and I cover the life science tools and diagnostics sector at Morgan Stanley. Im delighted to have Ginkgo join us today to open the conference and representing
the company is Anna Marie Wagner, SVP of Corporate Development and Investor Relations. So welcome Anna Marie. Before we get started, just a quick safe harbor for important disclosures.
Please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures, and if you have any questions, please do reach out to your
sales rep. So, with that, just to kick things off Anna Marie, for people on the webcast who are not as familiar with synthetic biology or the Ginkgo story, could you just give us a two-minute overview of who
Ginkgo is, what do you do, and where you are in terms of your journey to becoming a public company?
Anna Marie Wagner (00:53):
Sure. Yeah, theres a lot in there, but Ill do my best to get it in two minutes. If I forget anything, you can keep me honest. So synthetic biology
is the idea that we should be able to program cells, which are little biological machines, in the same way that we can program computers. It runs on digital code. It just happens to be A, C, T and G instead of 0 and 1, but we can read that code with
DNA sequencing and we can write that code with DNA synthesis, and if you can read code and you can write code and you have a machine that can run it, in this case, a cell, then you should be able to program it, and so Ginkgo was started really with
this idea and our heritage, if you look at our founders, is in that sector.
So, Tom Knight, whos sort of the godfather of Ginkgo and one of our co-founders, was a professor at MIT starting in kind of the seventies in the electrical engineering department and he worked on mainframes. He has this beautiful picture of him in the seventies with this
minicomputer, which is the size of a refrigerator, but he lived through four decades worth of building the infrastructure to make computers easily programmable. Something that we all take for granted today. And in the early nineties, to his great
credit, hes in his mid-forties at this point, hes like, look, all the hard problems have been solved in computing. This is starting to get boring.
What can I go tackle next, and he sort of has this realization about biology that its programmable, puts himself through the equivalent of a biology PhD
at MIT, builds a wet lab in the computer science department and brings together all of these engineers from different disciplines, and thats how he met the other four co-founders of Ginkgo. One was a
chemical engineer, one was a mechanical engineer, one was a biologist, and one was a computer scientist. So, this eclectic mix of engineering-oriented folks coming together to try to create this new engineering discipline in biology, which to that
point, had really been a craft art. Wed been programming cells for a while, but it was artistic. It was a craft.